Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Home » BETTER-B: new study wants to test treatment for breathlessness in COPD and ILD patients
A study called BETTER-B, led by Professor Irene Higginson, wants to test a new treatment. This is a medicine called mirtazapine. Mirtazapine is an antidepressant that has been used for many years. In small regular doses it may help to relieve severe breathlessness in people who are not depressed.
Breathlessness affects people with chronic obstructive pulmonary (COPD) or interstitial lung disease (ILD), often even after the underlying causes are treated. There are very few treatments for this symptom.
The study team plan to recruit 324 people across the UK, Germany, Ireland, Italy and Poland. They will compare treatment with either mirtazapine or a placebo (dummy drug) tablet.
If you meet the following criteria, you may be eligible to take part:
If you meet the criteria above and are interested in taking part in the study please contact: better-b@kcl.ac.uk . They will discuss the study with you in more detail and confirm whether you are eligible. If you would like more information about the study and resources for breathlessness, please visit the project website: https://betterbreathe.eu/.
BETTER-B is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825319.
Sign up to get the latest information and research on lung conditions, hear about our upcoming events and campaigns, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79